John Mendlein information

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's terms of use. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. (September 2017) The topic of this article may not meet Wikipedia's notability guideline for biographies. Please help to demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted. Find sources: "John Mendlein" – news · newspapers · books · scholar · JSTOR (May 2022) (Learn how and when to remove this message) This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (September 2023) (Learn how and when to remove this message)

John Mendlein is a biotech executive who has held leadership positions in biotech companies in Boston, San Diego and Toronto.^[1]

Mendlein served as a board member, general counsel and chief knowledge officer at Aurora Biosciences Corporation (Nasdaq: ABSC), a company co-founded by Nobel laureate Roger Y. Tsien and since acquired by Vertex Pharmaceuticals (Nasdaq: VRTX) for more than $590 million.^[2]

He served as chairman and chief executive officer of Affinium Pharmaceuticals, Ltd., which was founded by Tak Wah Mak, Aled Edwards, Cheryl Arrowsmith and Jack Greenblatt and since acquired by Debiopharm Group for Phase 2 asset based on a novel antibiotic target.^[3]

Mendlein served as the CEO of Adnexus Therapeutics, a Boston, Massachusetts-based biotech company founded by Flagship Ventures and acquired by Bristol-Myers Squibb (NYSE: BMY) for over $500M in 2008.^[4] The technology platform was based on the work of Jack W. Szostak, 2009 Nobel Laureate for Physiology or Medicine. In 2017 by Bristol-Myers partnered one of the Adnexus programs to Roche, an anti-myotstatin program that has completed phase-2 testing in Duchenne patients.

After Adnexus, Mendlein helped found Fate Therapeutics (Nasdaq: FATE), a cell-based therapy company, in San Diego, and became its chairman.^[5]

He served on the board of directors of Monogram Biosciences, Inc., an HIV and oncology diagnostic company that was acquired by Laboratory Corporation of America Holdings in 2009.^[6]

He joined aTyr Pharma as executive chairman and later became CEO. aTyr was founded by Paul Schimmel and Xiang-Lei Yang. The company is focused on leveraging its broad intellectual property portfolio related to Physiocrines to develop protein therapeutics for the treatment of various rare diseases.^[7]

Mendlein is also a board member of Editas Medicine (Nasdaq: EDIT), Moderna Therapeutics and Axcella Health.

He is a founder and director of Homes for Sudan, a non-profit organization providing sustainable, fireproof homes for displaced families in Sudan. He also serves on the Biotechnology Innovation Organization (“BIO”) emerging-companies board and is a member of the scientific advisory board of the Ocean Discovery Institute.

Mendlein holds a Ph.D. in physiology and biophysics from the University of California, Los Angeles, a J.D. from the University of California, Hastings College of the Law, and a B.S. in biology from the University of Miami.